Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).

Clinical Trial Description


Study Design

NCT number NCT05063162
Study type Interventional
Source UCB Pharma
Contact UCB Cares
Phone 001844599
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date November 5, 2021
Completion date July 23, 2025